The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most well-known and successful leaders in the Bioscience Industry to its Board of Directors. Change in board composition is the result of a strategic refocus for the FRA, and those recently appointed to the board include: Donald M. Elliman, Jr.; William Freytag, PhD; James C. T. Linfield; and David Perez.

1.
Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of
Four Key Leaders in the Bioscience Industry to Its Board of Directors
The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most well‐known and successful
leaders in the Bioscience Industry to its Board of Directors. Change in board composition is the result of a
strategic refocus for the FRA, and those recently appointed to the board include: Donald M. Elliman, Jr.;
William Freytag, PhD; James C. T. Linfield; and David Perez.
Aurora, CO, November 15, 2011 ‐ In a strategic effort to refocus and strengthen its organization, the
Fitzsimons Redevelopment Authority (FRA) has completed a regimen of planning to make adjustments in the
direction, roles, responsibilities and allocation of resources going forward. The announcement is made by
Denise Brown, FRA Interim Executive Director, who says, "Our first tactic in refocus involves augmenting our
board of directors with four of the area's most well‐known and successful leaders in the bioscience industry to
help build programs and services to attract bioscience companies to relocate to Colorado and keep growing
Colorado‐based bioscience companies here, adding to our employment base. The action to modify the board
accordingly was approved in a recent board action."
Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for
Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital
Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T.
Linfield, Partner‐in‐Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief
Executive Officer of CaridianBCT, becoming TerumoBCT.
Brown continues, "We're very pleased to welcome our new board members. These leaders are actively
involved the bioscience community ‐ locally, nationally and internationally ‐ and maintain those critical
relationships with entrepreneurs, companies and research groups required to guide the FRA through its next
phase of growth. This is the first time the FRA has had bioscience executives on its board."
As background, in 1996, the City of Aurora and University of Colorado worked together to create a special‐
purpose governmental entity, giving it a single mission: to imagine and govern the evolution of a historic army
medical center into one of the world’s most forward‐looking bioscience districts. In partnership with the
University of Colorado and the City of Aurora, the FRA acquired much of the former army site and began to
implement an ambitious redevelopment plan that now comprises the growing and thriving Fitzsimons Life
Science District that includes the Colorado Science + Technology Park now adjacent to the Anschutz Medical
Campus and the new V.A. hospital campus.
"As the Fitzsimons site has matured, it's become clear to the FRA board that it needed to do more to support
the growth of early‐stage Colorado bioscience companies, especially those developing technologies from
Colorado's research institutions, with an emphasis on those technologies developed at the Anschutz Medical
Campus. Hence, the FRA is now addressing the critical need to bring bioscience‐focused leadership to the
board process in building new corporate partnerships and leveraging the strength of the Anschutz Medical
Campus and the FRA's real estate development partner, the Forest City Science + Technology Group," Brown
explains.
‐More‐

2. Page 2
New FRA Board Members ‐ Bioscience Industry Leadership
Donald M. Elliman, Jr. (representing Children’s Hospital Colorado on the FRA Board) ‐‐ In February of 2011, Mr.
Elliman was named Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell
Biology. From June of 2009 to January of 2011, Don served as Chief Operating Officer for Colorado. In that position
he assisted the Governor in the management of all State agencies. He was also the Chair of the Colorado Recovery
Accountability Board, with responsibilities for oversight of spending in Colorado under the American Recovery and
Reinvestment Act. From 2007 to 2009, he was Director of the Colorado Office of Economic Development and
International Trade, and from 2000 to 2004, he served first as President of Ascent Sports and then as President of
Kroenke Sports Enterprises. He retired from Kroenke as he became Chair of the Children’s Hospital Board and co‐
chair of the campaign to raise funds for the new Hospital. Prior to his time at Kroenke, Mr. Elliman worked at Time
Warner for thirty‐two years, retiring as an Executive Vice President of Time Inc. He currently serves on the Boards
of Children’s Hospital Colorado, Middlebury College, Colorado State University and The Gates Family Foundation.
William Freytag, PhD ‐‐ Dr. Freytag currently serves as a member of the board of directors for three health care
companies: GlobeImmune, BaroFold, and BiOptix Inc. Dr. Freytag was Chairman and Chief Executive Officer of
Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January 2008. Prior to Aspreva, Dr.
Freytag was President, Chief Executive Officer and Chairman of the Board of Directors of Myogen, Inc., a company
that started in the bioscience incubator at Fitzsimons, from July 1998 until Myogen was acquired by Gilead Sciences
in November 2006. From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc.
Prior to Somatogen, Dr Freytag was President of Research and Development at Boehringer Mannheim Corporation,
an international healthcare company. He received a B.S. from Purdue University and a Ph.D. in biochemistry from
the University of Kansas Medical Center.
James C. T. Linfield ‐‐ As Partner‐in‐Charge of the Colorado office of Cooley LLP, Mr. Linfield's practice focuses on
representation of public and private technology companies and venture capital funds, with an emphasis on
corporate finance, mergers and acquisitions and strategic alliances. He has deep experience advising start‐ups,
venture‐backed companies, public entities and investors across a wide variety of industries, including
biotechnology and medical devices. Prior to joining Cooley, Mr. Linfield worked in the biotechnology industry for
two and a half years as Chief Financial Officer and General Counsel of Somatogen, Inc., where he helped lead the
company to a successful initial public offering. He received his A.B. magna cum laude from Harvard College and his
J.D. magna cum laude from Harvard Law School. He also serves as Chair of the Governor’s Advisory Committee on
Venture Capital Investment, is a member of the Executive Committee of the Colorado BioScience Association, and
is a member of the Technology Transfer Advisory Board for the University of Colorado.
David Perez ‐‐ As President and Chief Executive Officer of the combined businesses of CaridianBCT and Terumo
Transfusion—soon to be Terumo BCT, Mr. Perez also serves as Chairman of Terumo Corporation’s Blood
Management Business board. He is responsible for leading the strategic direction, growth and execution of this
combined global organization with revenues in excess of $830 million. Under his leadership direction, the
companies will integrate and innovate, together, to serve customers and their patients, who are the ultimate
beneficiaries of the lifesaving gift of blood. A dedicated and active industry leader with nearly 30 years of
experience within the medical device and health care industries, Mr. Perez also lends his expertise to numerous
boards and councils. He serves the Advanced Medical Technology Association (AdvaMed) on the board of directors
and on the Executive Committee, chairing both the Technology and Regulatory Affairs Committee and the Blood
Products and Technology Sector.
‐More‐

3. Page 3
Mr. Perez is also chair of the board of trustees for the National Blood Foundation (NBF); a member of the NBF
Council on Research and Development; and a board member of the Foundation for America's Blood Centers® and
the Colorado BioScience Association. Prior to joining CaridianBCT in 1999, he held leadership positions at
UroTherapies Inc., Haemonetics® Corp., Caremark LLC, Coram Healthcare Corp. and Kendall. Mr. Perez earned his
bachelor's degree in political science from Texas Tech University.
Other FRA Board members include: Bruce Benson, President, University of Colorado; Bruce Schroffel,
President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President for
Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Freund
Investments; and Councilwoman Melissa Miller from Aurora who will be joined by two other elected officials
to be named by the Aurora City Council.
About Fitzsimons Redevelopment Authority
The FRA directs the commercial developments in the Fitzsimons Life Science District, along with its partner,
Forest City Science + Technology Group. In this role, the FRA is dedicated to providing life science companies:
an environment where they can thrive; success‐enhancing resources like the District’s incubator facilities; and
services that help form connections between private industry and the University of Colorado. Aurora’s
Fitzsimons Life Science District is becoming what its founders envisioned: a functioning community that
directly supports the health and well‐being of life science companies. For more information, visit:
http://www.fitzscience.com.
# # #
Contacts:
Vicki Jenings, CPM, Director of Business Relations, Fitzsimons Redevelopment Authority ‐
http://www.fitzscience.com ‐ 720‐859‐4108 ‐ vjenings@colobio.com
Maggie Chamberlin Holben, APR, Principal ‐ Absolutely Public Relations ‐ http://www.absolutelypr.com ‐
303‐984‐9801 and 303‐669‐3558 (cell), maggie@absolutelypr.com